Search

Your search keyword '"Ben-Shoshan, Moshe"' showing total 1,148 results
Start Over Author "Ben-Shoshan, Moshe"
1,148 results on '"Ben-Shoshan, Moshe"'

102. Dupilumab Improves Urticaria Activity And Quality Of Life In Patients With Chronic Spontaneous Urticaria (CSU)

Author

Maurer, Marcus, primary, Casale, Thomas, additional, Saini, Sarbjot (Romi), additional, Ben-Shoshan, Moshe, additional, Radin, Allen, additional, Akinlade, Bolanle, additional, Fan, Chunpeng, additional, Bauer, Deborah, additional, Laws, Elizabeth, additional, Thomas, Ryan, additional, Mannent, Leda, additional, and Stjepanovic, Aleksandra, additional

Published
2023
Full Text
View/download PDF

104. Risk of Allergic Reactions in Children Who Attained Peanut Oral Immunotherapy (OIT) Maintenance

Author

Colli, Luca Delli, primary, Lawson, Benjamin, additional, Gabrielli, Sofianne, additional, Mazer, Bruce, additional, Ke, Danbing, additional, Zhang, Lydia, additional, Lejtenyi, Duncan, additional, Lucchesi, Chiara, additional, Beaudette, Liane, additional, Upton, Julia, additional, Grunebaum, Eyal, additional, Piccirillo, Ciro, additional, Chan, Edmond, additional, Clarke, Ann, additional, Zhang, Xun, additional, McCusker, Christine, additional, and Ben-Shoshan, Moshe, additional

Published
2023
Full Text
View/download PDF

106. Assessing Allergic Reactions to Cephalosporins in Children

Author

Sillcox, Carly, primary, O’Keefe, Andrew, additional, McCusker, Christine, additional, Gabrielli, Sofianne, additional, Abrams, Elissa, additional, Eiwegger, Thomas, additional, Atkinson, Adelle, additional, Kim, Vy, additional, Copaescu, Ana-Maria, additional, and Ben-Shoshan, Moshe, additional

Published
2023
Full Text
View/download PDF

107. Wheat-Induced Anaphylaxis in Pediatric Patients from the Cross-Canada Anaphylaxis Registry (C-CARE): Clinical Characteristics and Management

Author

Perlman, Lauren, primary, Gabrielli, Sofianne, additional, Clarke, Ann, additional, Colli, Luca Delli, additional, Colli, Marina Delli, additional, Morris, Judy, additional, Gravel, Jocelyn, additional, Lim, Rod, additional, Chan, Edmond, additional, Goldman, Ran, additional, O'Keefe, Andrew, additional, Gerdts, Jennifer, additional, Chu, Derek, additional, Upton, Julia, additional, Hochstadter, Elana, additional, Moisan, Jocelyn, additional, Bretholz, Adam, additional, McCusker, Christine, additional, Zhang, Xun, additional, Protudjer, Jennifer, additional, Abrams, Elissa, additional, Simons, Elinor, additional, and Ben-Shoshan, Moshe, additional

Published
2023
Full Text
View/download PDF

108. How low can we go: preliminary efficacy of very low dose peanut oral immunotherapy

Author

Upton, Julia, primary, Lejteyni, Duncan, additional, Ke, Danbing, additional, Berenjy, Alireza, additional, Beaudette, Liane, additional, McCusker, Christine, additional, Yin, Xiaojun, additional, Li, Carmen, additional, Duan, Lucy, additional, Marzouk, Shireen, additional, Grunebaum, Eyal, additional, Eiwegger, Thomas, additional, and Ben-Shoshan, Moshe, additional

Published
2023
Full Text
View/download PDF

115. De-Labelling Penicillin Allergy in the Emergency Department

Author

Alqurashi, Waleed, primary, Le Saux, Nicole, additional, Vyles, David, additional, Byrne, Adam, additional, Ben-Shoshan, Moshe, additional, Sucha, E., additional, Barrowman, Nick, additional, McGahern, Candice, additional, Dawson, Lauren, additional, and Plint, Amy, additional

Published
2023
Full Text
View/download PDF

116. Effects of Prescription Medications on Clinical Outcomes in Adults Presenting with Anaphylaxis

Author

Sehayek, Daniel, primary, Clarke, Ann, additional, Abrams, Elissa, additional, Bretholz, Adam, additional, Chan, Edmond, additional, Chu, Derek, additional, Gerdts, Jennifer, additional, Goldman, Ran, additional, Hochstadter, Elana, additional, Lim, Rodrick, additional, McCusker, Christine, additional, Moisan, Jocelyn, additional, Morris, Judy, additional, O’Keefe, Andrew, additional, Protudjer, Jennifer, additional, Simons, Elinor, additional, Upton, Julia, additional, Zhang, Xun, additional, and Ben-Shoshan, Moshe, additional

Published
2023
Full Text
View/download PDF

117. Temporal trends in anaphylaxis ED visits over the last decade and the effect of COVID-19 pandemic on these trends

Author

Al Ali, Adnan, primary, Gabrielli, Sofianne, additional, Delli Colli, Luca, additional, Delli Colli, Marina, additional, McCusker, Christine, additional, Clarke, Ann E, additional, Morris, Judy, additional, Gravel, Jocelyn, additional, Lim, Rodrick, additional, Chan, Edmond S., additional, Goldman, Ran D., additional, O’Keefe, Andrew, additional, Gerdts, Jennifer, additional, Chu, Derek K., additional, Upton, Julia, additional, Hochstadter, Elana, additional, Moisan, Jocelyn, additional, Bretholz, Adam, additional, Zhang, Xun, additional, Protudjer, Jennifer LP, additional, Abrams, Elissa M., additional, Simons, Elinor, additional, and Ben-Shoshan, Moshe, additional

Published
2023
Full Text
View/download PDF

118. Safety of COVID-19 mRNA vaccination in children with chronic urticaria

Author

Zhu, Catherine K., primary, Nguyen, Alex, additional, Prosty, Connor, additional, Gabrielli, Sofianne, additional, Laboccetta, Vera, additional, Shand, Greg, additional, Mulé, Pasquale, additional, Netchiporouk, Elena, additional, Le, Michelle, additional, Zhang, Xun, additional, Ke, Danbing, additional, Baum, Sharon, additional, Hakroush, Reman, additional, Greenberger, Shoshana, additional, and Ben-Shoshan, Moshe, additional

Published
2023
Full Text
View/download PDF

120. Bridging Knowledge Gaps in Anaphylaxis Management Through a Video-Based Educational Tool

Author

Karim, Jumanah, primary, Gabrielli, Sofianne, additional, Torabi, Bahar, additional, Byrne, Adam, additional, De Schryver, Sarah, additional, Gadoury-Lévesque, Vanessa, additional, Alizadehfar, Reza, additional, McCusker, Christine, additional, Vincent, Matthieu, additional, Morris, Judy, additional, Gerdts, Jennifer, additional, Zhang, Xun, additional, and Ben-Shoshan, Moshe, additional

Published
2022
Full Text
View/download PDF

121. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria

Author

Kocatürk, Emek, Salman, Andaç, Cherrez-Ojeda, Ivan, Criado, Paulo Ricardo, Peter, Jonny, Comert-Ozer, Elif, Abuzakouk, Mohamed, Câmara Agondi, Rosana, Al-Ahmad, Mona, Altrichter, Sabine, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Bauer, Andrea, Ben-Shoshan, Moshe, Bernstein, Jonathan, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Busse, Paula, Campos, Regis A., Carne, Emily, Conlon, Niall, Criado, Roberta Fachini Jardim, De Souza Lima, Eduardo Magalhães, Demir, Semra, Dissemond, Joachim, Doğan Günaydın, Sibel, Dorofeeva, Irina, Ensina, Luis Felipe, Ertaş, Ragip, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fomina, Daria, Franken, Sylvie M., Fukunaga, Atsushi, Giménez Arnau, Ana M, Godse, Kiran, Gonçalo, Margarida, Gotua, Maia, Grattan, Clive, Guillet, Carole, Inomata, Naoko, Jakob, Thilo, Karakaya, Gul, Kasperska-Zając, Alicja, Katelaris, Constance H., Košnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M.Sendhil, Lang, Claudia, Larco-Sousa, José Ignacio, Lazaridou, Elisavet, Leslie, Tabi Anika, Lippert, Undine, Calderón llosa, Oscar, Makris, Michael, Marsland, Alexander, Medina, Iris V., Meshkova, Raisa, Bastos Palitot, Esther, Parisi, Claudio A.S., Pickert, Julia, Ramon, Germán D., Rodríguez-Gonzalez, Mónica, Rosario, Nelson, Rudenko, Michael, Rutkowski, Krzysztof, Sánchez Caraballo, Jorge Mario, Schliemann, Sibylle, Sekerel, Bulent Enis, Serpa, Faradiba S., Serra-Baldrich, E, Song, Zhiqiang, Soria, Angèle, Staevska, Maria, Staubach, Petra, Tagka, Anna, Takahagi, Shunsuke, Thomsen, Simon Francis, Treudler, Regina, Vadasz, Zahava, Rodrigues Valle, Solange Oliveira, Van Doorn, Martijn B.A., Vestergaard, Christian, Wagner, Nicola, Wang, Dahu, Wang, Liangchun, Wedi, Bettina, Xepapadaki, Paraskevi, Yücel, Esra, Zalewska-Janowska, Anna, Zhao, Zuotao, Zuberbier, Torsten, Maurer, Marcus, Universitat Autònoma de Barcelona, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Salman, A., Cherrez-Ojeda, I., Criado, P. R., Peter, J., Comert-Ozer, E., Abuzakouk, M., Agondi, R. C., Al-Ahmad, M., Altrichter, S., Arnaout, R., Arruda, L. K., Asero, R., Bauer, A., Ben-Shoshan, M., Bernstein, J. A., Bizjak, M., Boccon-Gibod, I., Bonnekoh, H., Bouillet, L., Brzoza, Z., Busse, P., Campos, R. A., Carne, E., Conlon, N., Criado, R. F., Lima, E. M. D., Demir, S., Dissemond, J., Gunaydin, S. D., Dorofeeva, I., Ensina, L. F., Ertas, R., Ferrucci, S. M., Figueras-Nart, I., Fomina, D., Franken, S. M., Fukunaga, A., Gimenez-Arnau, A. M., Godse, K., Goncalo, M., Gotua, M., Grattan, C., Guillet, C., Inomata, N., Jakob, T., Karakaya, G., Kasperska-Zajac, A., Katelaris, C. H., Kosnik, M., Krasowska, D., Kulthanan, K., Kumaran, M. S., Lang, C., Larco-Sousa, J. I., Lazaridou, E., Leslie, T. A., Lippert, U., Llosa, O. C., Makris, M., Marsland, A., Medina, I. V., Meshkova, R., Palitot, E. B., Parisi, C. A. S., Pickert, J., Ramon, G. D., Rodriguez-Gonzalez, M., Rosario, N., Rudenko, M., Rutkowski, K., Sanchez, J., Schliemann, S., Sekerel, B. E., Serpa, F. S., Serra-Baldrich, E., Song, Z. Q., Soria, A., Staevska, M., Staubach, P., Tagka, A., Takahagi, S., Thomsen, S. F., Treudler, R., Vadasz, Z., Valle, S. O. R., Van Doorn, M. B. A., Vestergaard, C., Wagner, N., Wang, D. H., Wang, L. C., Wedi, B., Xepapadaki, P., Yücel, E., Zalewska-Janowska, A., Zhao, Z. T., Zuberbier, T., Maurer, M., School of Medicine, AII - Infectious diseases, Kocaturk, Emek, Salman, Andac, Cherrez-Ojeda, Ivan, Criado, Paulo Ricardo, Peter, Jonny, Comert-Ozer, Elif, Abuzakouk, Mohamed, Agondi, Rosana Camara, Al-Ahmad, Mona, Altrichter, Sabine, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Bauer, Andrea, Ben-Shoshan, Moshe, Bernstein, Jonathan A., Bizjak, Mojca, Boccon-Gibod, Isabelle, Bonnekoh, Hanna, Bouillet, Laurence, Brzoza, Zenon, Busse, Paula, Campos, Regis A., Carne, Emily, Conlon, Niall, Criado, Roberta F., de Souza Lima, Eduardo M., Demir, Semra, Dissemond, Joachim, Gunaydin, Sibel Dogan, Dorofeeva, Irina, Ensina, Luis Felipe, Ertas, Ragip, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fomina, Daria, Franken, Sylvie M., Fukunaga, Atsushi, Gimenez-Arnau, Ana M., Godse, Kiran, Goncalo, Margarida, Gotua, Maia, Grattan, Clive, Guillet, Carole, Inomata, Naoko, Jakob, Thilo, Karakaya, Gul, Kasperska-Zajac, Alicja, Katelaris, Constance H., Kosnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Lang, Claudia, Ignacio Larco-Sousa, Jose, Lazaridou, Elisavet, Leslie, Tabi Anika, Lippert, Undine, Llosa, Oscar Calderon, Makris, Michael, Marsland, Alexander, Medina, Iris, V, Meshkova, Raisa, Palitot, Esther Bastos, Parisi, Claudio A. S., Pickert, Julia, Ramon, German D., Rodriguez-Gonzalez, Monica, Rosario, Nelson, Rudenko, Michael, Rutkowski, Krzysztof, Sanchez, Jorge, Schliemann, Sibylle, Sekerel, Bulent Enis, Serpa, Faradiba S., Serra-Baldrich, Esther, Song, Zhiqiang, Soria, Angele, Staevska, Maria, Staubach, Petra, Tagka, Anna, Takahagi, Shunsuke, Thomsen, Simon Francis, Treudler, Regina, Vadasz, Zahava, Rodrigues Valle, Solange Oliveira, Van Doorn, Martijn B. A., Vestergaard, Christian, Wagner, Nicola, Wang, Dahu, Wang, Liangchun, Wedi, Bettina, Xepapadaki, Paraskevi, Yucel, Esra, Zalewska-Janowska, Anna, Zhao, Zuotao, Zuberbier, Torsten, and Maurer, Marcus

Subjects
Male, 0301 basic medicine, STRESS, Exacerbation, UCARE, pandemije, Medizin, Omalizumab, SERUM, chronic urticaria, 0302 clinical medicine, Pandemic, Health care, Immunology and Allergy, Chronic Urticaria, treatment, Chronic urticaria, COVID-19, Cyclosporine, SARS-CoV-2, Treatment, zdravljenje, ASSOCIATION, Middle Aged, cyclosporine, omalizumab, pandemic, kronična urtikarija, INFECTIONS, GA(2)LEN, Female, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Coronavirus disease 2019 (COVID-19), Immunology, udc:616-097, pandemics, ciklosporin, Young Adult, 03 medical and health sciences, Patient referral, medicine, Humans, In patient, Patient Reported Outcome Measures, Aged, Internet, business.industry, DEFINITION, Medicine, Allergy, Cross-Sectional Studies, 030104 developmental biology, 030228 respiratory system, Emergency medicine, business
Abstract

Introduction: the COVID-19 pandemic dramatically disrupts health care around the globe. The impact of the pandemic on chronic urticaria (CU) and its management are largely unknown. Aim: to understand how CU patients are affected by the COVID-19 pandemic; how specialists alter CU patient management; and the course of CU in patients with COVID-19. Materials and methods: our cross-sectional, international, questionnaire-based, multicenter UCARE COVID-CU study assessed the impact of the pandemic on patient consultations, remote treatment, changes in medications, and clinical consequences. Results: the COVID-19 pandemic severely impairs CU patient care, with less than 50% of the weekly numbers of patients treated as compared to before the pandemic. Reduced patient referrals and clinic hours were the major reasons. Almost half of responding UCARE physicians were involved in COVID-19 patient care, which negatively impacted on the care of urticaria patients. The rate of face-to-face consultations decreased by 62%, from 90% to less than half, whereas the rate of remote consultations increased by more than 600%, from one in 10 to more than two thirds. Cyclosporine and systemic corticosteroids, but not antihistamines or omalizumab, are used less during the pandemic. CU does not affect the course of COVID-19, but COVID-19 results in CU exacerbation in one of three patients, with higher rates in patients with severe COVID-19. Conclusions: the COVID-19 pandemic brings major changes and challenges for CU patients and their physicians. The long-term consequences of these changes, especially the increased use of remote consultations, require careful evaluation., Novartis; Sanofi; Menarini Universidad Espiritu Santo; Takeda; Allakos; AstraZeneca; CSL Behring; Genentech; Pharming; GSK; Shire/Takada; BioCryst; ResTORbio; Pearl Therapeutics, CVS Health; Law offices of Levin; Riback; Adelman; Flangel; Vedder Price; Fresenius; Taiho; Kyowa Kirin; Tanabe; Korin; Uriach Pharma; Instituto Carlos III FEDER; Menarini; Amgen; Thermo Fisher; Avene; ALK‐Abello; Bencard/Allergy Therapeutics; Celgene; Allergopharma; Faes Farma; AbbVie; Janssen; Leo Pharma; Lilly; Roche; Genesis; Menlo Therapeutics; UCB; Pfizer; Almirall; Galderma; Allergika; Beiersdorf; Biocryst; Biogen Idec; BMS; Boehringer‐Ingelheim; Eli‐Lilly; Galderma; Hexal; Klosterfrau; LEO‐Pharma; LETI‐Pharma; L´Oreal; Medice; Octapharma; Pflüger; Pharming; Regeneron; Shire; ALK‐Abello; Fraunhofer‐IZI Leipzig; Hautnetz Leipzig/Westsachsen; MSD; HAL‐Allergy; Bencard; Nestle; Nutricia; Bayer Health Care; FAES; Henkel; Allakos; Argenx; Genentech Menarini; Moxie; Aralez; Celldex

Published
2021

127. Genome-wide association study and meta-analysis in multiple populations identifies new loci for peanut allergy and establishes C11orf30/EMSY as a genetic risk factor for food allergy

Author

Asai, Yuka, Eslami, Aida, van Ginkel, Dorien C., Akhabir, Loubna, Wan, Ming, Ellis, George, Ben-Shoshan, Moshe, Martino, David, Ferreira, Manuel A., Allen, Katrina, Mazer, Bruce, de Groot, Hans, de Jong, Nicolette W., Gerth van Wijk, Roy N., Dubois, Anthony E.J., Chin, Rick, Cheuk, Stephen, Hoffman, Joshua, Jorgensen, Eric, Witte, John S., Melles, Ronald B., Hong, Xiumei, Wang, Xiaobin, Hui, Jennie, Musk, Arthur W. (Bill), Hunter, Michael, James, Alan L., Koppelman, Gerard H., Sandford, Andrew J., Clarke, Ann E., and Daley, Denise

Published
2018
Full Text
View/download PDF

129. Ligelizumab in adolescents with chronic spontaneous urticaria: Results of a dedicated phase 2b randomized clinical trial supported with pharmacometric analysis.

Author

Staubach, Petra, Alvaro‐Lozano, Montserrat, Sekerel, Bulent Enis, Maurer, Marcus, Ben‐Shoshan, Moshe, Porter, Miriam, Hua, Eva, Ji, Yan, Burciu, Alis, Savelieva, Marina, Severin, Thomas, Drollmann, Anton, and Bienczak, Andrzej

Subjects
TEENAGERS, URTICARIA, CLINICAL trials, DRUG development, MONOCLONAL antibodies
Abstract

Background: Chronic spontaneous urticaria (CSU), a long‐lasting disease in children, impacts their quality of life. We report the results of a phase 2b dose‐finding trial of ligelizumab (NCT03437278) and a high‐affinity humanized monoclonal anti‐IgE antibody, in adolescents with CSU, supported by modeling and simulation analyses, mitigating challenges in pediatric drug development. Methods: This multicenter, double‐blind, placebo‐controlled trial, randomized H1‐antihistamine‐refractory adolescent CSU patients (12–18 years) 2:1:1 to ligelizumab 24 mg, 120 mg, or placebo every 4 weeks for 24 weeks. Patients on placebo transitioned to ligelizumab 120 mg at week 12. Integrating data from the previous adult and present adolescent trial of ligelizumab, a nonlinear mixed‐effects modeling described the longitudinal changes in ligelizumab pharmacokinetics, and its effect on weekly Urticaria Activity Score (UAS7). Results: Baseline UAS7 (mean ± SD) was 30.5 ± 7.3 (n = 24), 29.3 ± 7.7 (n = 13), and 32.5 ± 9.0 (n = 12) for patients (median age, 15 years) on ligelizumab 24 mg, 120 mg, and placebo, respectively. Change from baseline in UAS7 at week 12 with ligelizumab 24 mg, 120 mg, and placebo was −15.7 ± 10.9, −18.4 ± 12.3, and −13.0 ± 13.0, respectively. Ligelizumab was well‐tolerated. The modeling analysis showed that body weight, but not age, affected ligelizumab's apparent clearance. No significant differences between adolescents and adults were detected on the model‐estimated maximum effect and potency. Conclusions: Ligelizumab exhibited efficacy and safety in adolescent CSU patients, consistent with that in adults. The PK and potency of ligelizumab were not impacted by age, and the same dose of ligelizumab can be used for treating adolescents and adults with CSU. Our study shows how modeling and simulation can complement pediatric drug development. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

130. Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial

Author

Copaescu, Ana Maria, Vogrin, Sara, James, Fiona, Chua, Kyra Y. L., Rose, Morgan T., De Luca, Joseph, Waldron, Jamie, Awad, Andrew, Godsell, Jack, Mitri, Elise, Lambros, Belinda, Douglas, Abby, Youcef Khoudja, Rabea, Isabwe, Ghislaine A. C., Genest, Genevieve, Fein, Michael, Radojicic, Cristine, Collier, Ann, Lugar, Patricia, Stone, Cosby, Ben-Shoshan, Moshe, Turner, Nicholas A., Holmes, Natasha E., Phillips, Elizabeth J., and Trubiano, Jason A.

Abstract

IMPORTANCE: Fewer than 5% of patients labeled with a penicillin allergy are truly allergic. The standard of care to remove the penicillin allergy label in adults is specialized testing involving prick and intradermal skin testing followed by an oral challenge with penicillin. Skin testing is resource intensive, limits practice to specialist-trained physicians, and restricts the global population who could undergo penicillin allergy delabeling. OBJECTIVE: To determine whether a direct oral penicillin challenge is noninferior to the standard of care of penicillin skin testing followed by an oral challenge in patients with a low-risk penicillin allergy. DESIGN, SETTING, AND PARTICIPANTS: This parallel, 2-arm, noninferiority, open-label, multicenter, international randomized clinical trial occurred in 6 specialized centers, 3 in North America (US and Canada) and 3 in Australia, from June 18, 2021, to December 2, 2022. Eligible adults had a PEN-FAST score lower than 3. PEN-FAST is a prospectively derived and internationally validated clinical decision rule that enables point-of-care risk assessment for adults reporting penicillin allergies. INTERVENTIONS: Patients were randomly assigned to either direct oral challenge with penicillin (intervention arm) or a standard-of-care arm of penicillin skin testing followed by oral challenge with penicillin (control arm). MAIN OUTCOME AND MEASURE: The primary outcome was a physician-verified positive immune-mediated oral penicillin challenge within 1 hour postintervention in the intention-to-treat population. Noninferiority was achieved if a 1-sided 95% CI of the risk difference (RD) did not exceed 5 percentage points (pp). RESULTS: A total of 382 adults were randomized, with 377 patients (median [IQR] age, 51 [35-65] years; 247 [65.5%] female) included in the analysis: 187 in the intervention group and 190 in the control group. Most patients had a PEN-FAST score of 0 or 1. The primary outcome occurred in 1 patient (0.5%) in the intervention group and 1 patient (0.5%) in the control group, with an RD of 0.0084 pp (90% CI, −1.22 to 1.24 pp). The 1-sided 95% CI was below the noninferiority margin of 5 pp. In the 5 days following the oral penicillin challenge, 9 immune-mediated adverse events were recorded in the intervention group and 10 in the control group (RD, −0.45 pp; 95% CI, −4.87 to 3.96 pp). No serious adverse events occurred. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, direct oral penicillin challenge in patients with a low-risk penicillin allergy was noninferior compared with standard-of-care skin testing followed by oral challenge. In patients with a low-risk history, direct oral penicillin challenge is a safe procedure to facilitate the removal of a penicillin allergy label. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04454229

Published
2023
Full Text
View/download PDF

131. The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1

Author

Depner, Mark, Fuchs, Sebastian, Raabe, Jan, Frede, Natalie, Glocker, Cristina, Doffinger, Rainer, Gkrania-Klotsas, Effrossyni, Kumararatne, Dinakantha, Atkinson, T. Prescott, Schroeder, Jr., Harry W., Niehues, Tim, Dückers, Gregor, Stray-Pedersen, Asbjørg, Baumann, Ulrich, Schmidt, Reinhold, Franco, Jose L., Orrego, Julio, Ben-Shoshan, Moshe, McCusker, Christine, Jacob, Cristina Miuki Abe, Carneiro-Sampaio, Magda, Devlin, Lisa A., Edgar, J. David M., Henderson, Paul, Russell, Richard K., Skytte, Anne-Bine, Seneviratne, Suranjith L., Wanders, Jennifer, Stauss, Hans, Meyts, Isabelle, Moens, Leen, Jesenak, Milos, Kobbe, Robin, Borte, Stephan, Borte, Michael, Wright, Dowain A., Hagin, David, Torgerson, Troy R., and Grimbacher, Bodo

Published
2016
Full Text
View/download PDF

132. Skin prick test in milk allergic patients undergoing oral immunotherapy: Does the milk form used for skin tests matter?

Author

Bukhari, Esraa, primary, Gabrielli, Sofianne, additional, McCusker, Christine, additional, Upton, Julia, additional, Grunebaum, Eyal, additional, Chan, Edmond S., additional, Beaudette, Liane, additional, Langlois, Alexandra, additional, Torabi, Bahar, additional, Lejtenyi, Duncan, additional, Clarke, Ann E., additional, Ke, Danbing, additional, Mazer, Bruce David, additional, and Ben-Shoshan, Moshe, additional

Published
2022
Full Text
View/download PDF

134. Changes in food-related costs during the COVID-19 pandemic among families managing food allergy

Author

Golding, Michael A., primary, Lemoine-Courcelles, Cathérine, additional, Abrams, Elissa M., additional, Ben-Shoshan, Moshe, additional, Bégin, Philippe, additional, Chan, Edmond S., additional, Chu, Derek K., additional, Gerdts, Jennifer D., additional, Povolo, Beatrice, additional, Kim, Harold, additional, Simons, Elinor, additional, Upton, Julia, additional, and Protudjer, Jennifer L. P., additional

Published
2022
Full Text
View/download PDF

136. Validation of UAS7 among children with chronic spontaneous urticaria

Author

Gabrielli, Sofianne, primary, Mulé, Pasquale, additional, Prosty, Connor, additional, Gooding, Gregory, additional, Le, Michelle, additional, Zhang, Lydia, additional, Netchiporouk, Elena, additional, Baum, Sharon, additional, Greenberger, Shoshana, additional, Ensina, Luis F., additional, Lovett, Audrey, additional, Zhang, Xun, additional, and Ben-Shoshan, Moshe, additional

Published
2022
Full Text
View/download PDF

138. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Author

Zuberbier, Torsten, Abdul Latiff, Amir Hamzah, Abuzakouk, Mohamed, Aquilina, Susan, Asero, Riccardo, Baker, Diane, Ballmer-Weber, Barbara, Bangert, Christine, Ben-Shoshan, Moshe, Bernstein, Jonathan A., Bindslev-Jensen, Carsten, Brockow, Knut, Brzoza, Zenon, Chong Neto, Herberto Jose, Church, Martin K., Criado, Paulo R., Danilycheva, Inna V., Dressler, Corinna, Ensina, Luis Felipe, Fonacier, Luz, Gaskins, Matthew, Gáspár, Krisztian, Gelincik, Aslı, Giménez-Arnau, Ana, Godse, Kiran, Gonçalo, Margarida, Grattan, Clive, Grosber, Martine, Hamelmann, Eckard, Hébert, Jacques, Hide, Michihiro, Kaplan, Allen, Kapp, Alexander, Kessel, Aharon, Kocatürk, Emek, Kulthanan, Kanokvalai, Larenas-Linnemann, Désirée, Lauerma, Antti, Leslie, Tabi A., Magerl, Markus, Makris, Michael, Meshkova, Raisa Y., Metz, Martin, Micallef, Daniel, Mortz, Charlotte G., Nast, Alexander, Oude-Elberink, Hanneke, Pawankar, Ruby, Pigatto, Paolo D., Ratti Sisa, Hector, Rojo Gutiérrez, María Isabel, Saini, Sarbjit S., Schmid-Grendelmeier, Peter, Sekerel, Bulent E., Siebenhaar, Frank, Siiskonen, Hanna, Soria, Angele, Staubach-Renz, Petra, Stingeni, Luca, Sussman, Gordon, Szegedi, Andrea, Thomsen, Simon Francis, Vadasz, Zahava, Vestergaard, Christian, Wedi, Bettina, Zhao, Zuotao, Maurer, Marcus, Zuberbier, Torsten, Abdul Latiff, Amir Hamzah, Abuzakouk, Mohamed, Aquilina, Susan, Asero, Riccardo, Baker, Diane, Ballmer-Weber, Barbara, Bangert, Christine, Ben-Shoshan, Moshe, Bernstein, Jonathan A., Bindslev-Jensen, Carsten, Brockow, Knut, Brzoza, Zenon, Chong Neto, Herberto Jose, Church, Martin K., Criado, Paulo R., Danilycheva, Inna V., Dressler, Corinna, Ensina, Luis Felipe, Fonacier, Luz, Gaskins, Matthew, Gáspár, Krisztian, Gelincik, Aslı, Giménez-Arnau, Ana, Godse, Kiran, Gonçalo, Margarida, Grattan, Clive, Grosber, Martine, Hamelmann, Eckard, Hébert, Jacques, Hide, Michihiro, Kaplan, Allen, Kapp, Alexander, Kessel, Aharon, Kocatürk, Emek, Kulthanan, Kanokvalai, Larenas-Linnemann, Désirée, Lauerma, Antti, Leslie, Tabi A., Magerl, Markus, Makris, Michael, Meshkova, Raisa Y., Metz, Martin, Micallef, Daniel, Mortz, Charlotte G., Nast, Alexander, Oude-Elberink, Hanneke, Pawankar, Ruby, Pigatto, Paolo D., Ratti Sisa, Hector, Rojo Gutiérrez, María Isabel, Saini, Sarbjit S., Schmid-Grendelmeier, Peter, Sekerel, Bulent E., Siebenhaar, Frank, Siiskonen, Hanna, Soria, Angele, Staubach-Renz, Petra, Stingeni, Luca, Sussman, Gordon, Szegedi, Andrea, Thomsen, Simon Francis, Vadasz, Zahava, Vestergaard, Christian, Wedi, Bettina, Zhao, Zuotao, and Maurer, Marcus

Abstract

This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria.

Published
2022

141. The Risk of Recurrent Anaphylaxis

Author

OʼKeefe, Andrew, Clarke, Ann, St. Pierre, Yvan, Mill, Jennifer, Asai, Yuka, Eisman, Harley, La Vieille, Sebastien, Alizadehfar, Reza, Joseph, Lawrence, Morris, Judy, Gravel, Jocelyn, and Ben-Shoshan, Moshe

Published
2017
Full Text
View/download PDF

145. Table S1 - Supplemental material for Systemic Disease Association With Multiple Eruptive Dermatofibromas: A Systematic Review

Author

Ridha, Zainab, Belmesk, Lina, Jfri, Abdulhadi, Gabrielli, Sofianne, AlHalees, Zeinah, Ben-Shoshan, Moshe, Zhang, Xun, and Netchiporouk, Elena

Subjects
Medicine
Abstract

Supplemental material, Table S1, for Systemic Disease Association With Multiple Eruptive Dermatofibromas: A Systematic Review by Zainab Ridha, Lina Belmesk, Abdulhadi Jfri, Sofianne Gabrielli, Zeinah AlHalees, Moshe Ben-Shoshan, Xun Zhang and Elena Netchiporouk in Journal of Cutaneous Medicine and Surgery

Published
2022
Full Text
View/download PDF

146. Figure S1 - Supplemental material for Systemic Disease Association With Multiple Eruptive Dermatofibromas: A Systematic Review

Author

Ridha, Zainab, Belmesk, Lina, Jfri, Abdulhadi, Gabrielli, Sofianne, AlHalees, Zeinah, Ben-Shoshan, Moshe, Zhang, Xun, and Netchiporouk, Elena

Subjects
Medicine
Abstract

Supplemental material, Figure S1, for Systemic Disease Association With Multiple Eruptive Dermatofibromas: A Systematic Review by Zainab Ridha, Lina Belmesk, Abdulhadi Jfri, Sofianne Gabrielli, Zeinah AlHalees, Moshe Ben-Shoshan, Xun Zhang and Elena Netchiporouk in Journal of Cutaneous Medicine and Surgery

Published
2022
Full Text
View/download PDF

147. Duration of skin prick test refractory period following food‐induced allergic reactions.

Author

Mulé, Pasquale, Prosty, Connor, Mazer, Bruce, Ke, Danbing, Lejtenyi, Duncan, Beaudette, Liane, Upton, Julia, Chan, Edmond S., Clarke, Ann, Zhang, Xun, Gabrielli, Sofianne, and Ben‐Shoshan, Moshe

Subjects
ALLERGIES, SKIN tests, PEANUT allergy, VENOM hypersensitivity, MILK allergy, FOOD allergy
Abstract

Keywords: allergic reaction; allergy diagnosis; anaphylaxis; food allergy; skin prick test EN allergic reaction allergy diagnosis anaphylaxis food allergy skin prick test 1059 1061 3 10/09/23 20231001 NES 231001 Key messages A 4-6-week refractory period for skin prick testing following allergic reaction is commonly assumed. Allergic reaction, allergy diagnosis, anaphylaxis, food allergy, skin prick test Duration of skin prick test refractory period following food-induced allergic reactions. [Extracted from the article]

Published
2023
Full Text
View/download PDF

149. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy

Author

Brown, Sara J., Asai, Yuka, Cordell, Heather J., Campbell, Linda E., Zhao, Yiwei, Liao, Haihui, Northstone, Kate, Henderson, John, Alizadehfar, Reza, Ben-Shoshan, Moshe, Morgan, Kenneth, Roberts, Graham, Masthoff, Laury J.N., Pasmans, Suzanne G.M.A., van den Akker, Peter C., Wijmenga, Cisca, Hourihane, Jonathan O’B., Palmer, Colin N.A., Lack, Gideon, Clarke, Ann, Hull, Peter R., Irvine, Alan D., and McLean, W. H. Irwin

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results